Drug Profile
Baminercept
Alternative Names: BG 9924; LTβR-Ig; Lymphotoxin-β receptor fusion proteinLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen Idec; National Institute of Allergy and Infectious Diseases
- Class Antirheumatics; Recombinant fusion proteins
- Mechanism of Action Lymphotoxin beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sjogren's syndrome
- Discontinued Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 11 Oct 2018 No recent reports on development identified - Phase-II for Sjogren's syndrome in USA (SC)
- 01 Nov 2015 The National Institute of Allergy and Infectious Diseases completes phase II trial in Sjögren's syndrome in USA (NCT01552681)
- 04 Feb 2011 Phase-II clinical trials in Ulcerative colitis (SC)